Fresenius Acquires Full Ownership of mAbxience

Fresenius SE & Co. KGaA has acquired the remaining 45% of mAbxience from Insud Pharma, securing full ownership and building upon their partnership established in 2022. This strategic move aims to enhance the quality and resilience of supply chains while pushing for future innovations in biosimilars.

Since acquiring a majority stake in August 2022, Fresenius has integrated mAbxience into its Biopharma unit, encompassing the entire value chain from development to commercialization. The acquisition builds on milestones in development, manufacturing, and regulatory fields. It enhances Fresenius's ability to control costs and capacity while leveraging market opportunities as biologics lose exclusivity.

Michael Sen, CEO of Fresenius, advocates this milestone as essential for a robust vertically-integrated biopharma business. Meanwhile, mAbxience CEO, Jurgen van Broeck, emphasizes the enhanced platform for innovation and long-term growth.